SYRE · Categories · Form 4

SYRE - SEC Form 4 insider transactions

Spyre Therapeutics Inc. (SYRE) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for SYRE

• 22d
  SEC Form 4 filed by Turtle Cameron

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 22d
  SEC Form 4 filed by Sloan Sheldon

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 22d
  SEC Form 4 filed by Burrows Scott L

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 53d
  Chief Financial Officer Burrows Scott L exercised 2,500 shares at a strike of $14.50 and sold $101,620 worth of shares (2,500 units at $40.65) (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 53d
  Chief Executive Officer Turtle Cameron sold $632,866 worth of shares (15,000 units at $42.19), decreasing direct ownership by 2% to 642,540 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 80d
  Chief Executive Officer Turtle Cameron sold $492,045 worth of shares (15,000 units at $32.80), decreasing direct ownership by 2% to 657,540 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 92d
  Director Henderson Michael Thomas acquired 63,227 shares, increasing direct ownership by 60% to 168,606 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 102d
  SEC Form 4 filed by Chief Financial Officer Burrows Scott L

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 102d
  SEC Form 4 filed by Chief Executive Officer Turtle Cameron

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 102d
  SEC Form 4 filed by Chief Medical Officer Sloan Sheldon

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 102d
  SEC Form 4 filed by Officer King-Jones Heidy

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 109d
  Chief Executive Officer Turtle Cameron sold $460,134 worth of shares (15,000 units at $30.68), decreasing direct ownership by 2% to 671,907 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 143d
  Chief Executive Officer Turtle Cameron sold $435,356 worth of shares (15,000 units at $29.02), decreasing direct ownership by 2% to 686,907 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 171d
  Chief Executive Officer Turtle Cameron sold $1,049,778 worth of shares (45,000 units at $23.33), decreasing direct ownership by 6% to 701,907 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 234d
  Chief Financial Officer Burrows Scott L sold $299,639 worth of shares (18,428 units at $16.26), decreasing direct ownership by 16% to 97,994 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Fairmount Funds Management Llc

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Stelzer Laurie

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Milligan Sandra

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Mckenna Mark C.

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Henderson Michael Thomas

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 328d
  SEC Form 4 filed by Director Albers Jeffrey W.

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 463d
  SEC Form 4 filed by Chief Financial Officer Burrows Scott L

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 463d
  SEC Form 4 filed by Chief Medical Officer Sloan Sheldon

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 463d
  SEC Form 4 filed by Chief Executive Officer Turtle Cameron

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 463d
  SEC Form 4 filed by Officer King-Jones Heidy

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 466d
  Director Henderson Michael Thomas acquired 105,379 shares (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 533d
  Director Albers Jeffrey W. sold $246,313 worth of shares (6,700 units at $36.76) (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 545d
  Director Albers Jeffrey W. sold $10,929 worth of shares (300 units at $36.43) (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 571d
  SEC Form 4 filed by Chief Medical Officer Sloan Sheldon

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 598d
  Chief Financial Officer Burrows Scott L sold $522,074 worth of shares (18,531 units at $28.17), decreasing direct ownership by 14% to 116,422 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 710d
  SEC Form 4 filed by Fairmount Funds Management Llc

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 710d
  SEC Form 4 filed by Albers Jeffrey W.

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 710d
  SEC Form 4 filed by Milligan Sandra

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 710d
  SEC Form 4 filed by Henderson Michael Thomas

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 710d
  SEC Form 4 filed by Stelzer Laurie

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 731d
  Fairmount Funds Management Llc converted options into 3,639,680 shares (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
• 795d
  Turtle Cameron was granted 400 shares, increasing direct ownership by 0.05% to 746,907 units (SEC Form 4)

  4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

Other SYRE categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends